Biomerica Inc Dossier - Source-backed chat

Biomerica Inc

BMRANASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.53

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.24Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $10.3M

Enterprise Value $9.2M

Shares Outstanding 4.6M diluted

Next Earnings Date15 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biomerica is transitioning from a low-margin legacy diagnostic business to a high-margin, clinically validated diagnostic-guided therapy model, anchored by its flagship inFoods IBS platform. The establishment of a $300 national Medicare payment rate effective January 1, 2026, and the signing of a $1.75 million CDMO Master Services Agreement in May 2026 provide strong commercial validation and near-term revenue visibility. However, the company continues to face near-term revenue challenges (TTM revenue down 23.8% to $4.33 million) and persistent operating losses. While the balance sheet is debt-light, cash reserves remain tight ($1.34 million as of Q3 FY2026), suggesting potential dilution risk from ATM usage. A Hold recommendation is advised until commercial execution of the inFoods IBS test scales and the CDMO contract begins to meaningfully offset the legacy business decline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial adoption of inFoods IBS is hindered by slow MAC coverage approvals and resistance from private payers. Legacy product sales continue to decline, and the CDMO partner delays Statements of Work, forcing Biomerica to aggressively utilize its ATM facility, leading to significant shareholder dilution.

Base CaseCentral scenario

The company successfully leverages the $300 Medicare benchmark to secure private payer coverage and scales inFoods IBS sales through its marketing agreement with Henry Schein and international partners. CDMO milestones are executed on schedule, contributing to a gradual gross margin expansion toward 30% and narrowing net losses over the next 12-18 months.

Bull CaseUpside scenario

Biomerica's growth is driven by its proprietary diagnostic-guided therapy platform, inFoods IBS, which has demonstrated clinically significant results in a randomized, double-blind clinical trial published in Gastroenterology. The test identifies patient-specific food triggers to guide personalized dietary elimination, showing a 59.6% abdominal pain reduction response rate (meeting FDA endpoints) compared to 42.2% in the control group, with particularly strong efficacy in underserved IBS-M (66.0%) and IBS-C (67.1%) patient populations. Commercialization is scaling through partnerships with large GI physician groups, a CLIA lab partner for insurance reimbursement, and potential out-licensing opportunities. Additionally, the company's growth is supported by its FDA-cleared Hp Detect Stool Antigen ELISA test for H. pylori and international regulatory approvals, such as the UAE Ministry of Health's approval of the Fortel Ulcer Test for home use.

Scenarios reflect our research view at the research date.

Key Investment Merits

Established $300 national Medicare payment rate for inFoods IBS provides a strong pricing floor and commercial benchmark.
New $1.75 million CDMO Master Services Agreement validates Biomerica's FDA-licensed, ISO 13485-certified manufacturing capabilities and provides near-term revenue visibility.
Flagship inFoods IBS test is backed by robust, peer-reviewed clinical data published in Gastroenterology, showing significant patient outcomes.
Debt-light balance sheet with only $193,000 in total debt against $1.34 million in cash as of Q3 FY2026.

Key Investment Risks

Persistent operating losses and negative cash flows from operations ($3.17 million TTM operating cash outflow).
Revenue concentration and volatility in legacy diagnostic lines, with TTM revenue declining 23.8% to $4.33 million.
Dilution risk from potential future equity raises under the company's active shelf registration and ATM program to fund working capital.
Dependence on third-party distributors and laboratory partners for commercial execution and billing.

Thesis Invalidation Triggers

Failure to transition individual Medicare claim reviews into broad local or national coverage determinations.
Termination or material delay of Statements of Work under the newly signed $1.75 million CDMO agreement.
Cash reserves falling below $500,000 without alternative non-dilutive funding, triggering going-concern warnings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.